5AM Ventures

5AM Ventures Research Investment Thesis & Philosophy 5AM Ventures is a leading life sciences venture capital firm founded in 2002, headquartered in San Francisco with significant operations in Boston. The firm manages $450M from 5AM Ventures VII and $300M from 5AM Opportunities II, positioning it as one of the most experienced and successful biotech VCs. The firm's core investment thesis centers on funding and building next-generation life sciences companies that solve important healthcare needs through cutting-edge breakthroughs in medicine and science. 5AM is driven by an "old-fashioned" VC style of working closely with portfolio companies, going beyond passive board roles to assume short-term operating roles and proactively provide guidance throughout a portfolio company's life. The firm positions itself as "entrepreneur-friendly" with team members who have spent careers in the life science industry, often working together over many years. The team collectively brings over a century of combined operational experience as CEOs and other leadership roles at life science companies. Investment Focus & Stage Preferences Core Focus Areas: Biopharmaceuticals Drug delivery technologies Life science instruments Therapeutic innovation across all major therapeutic areas Rare diseases, genetic medicines, respiratory diseases, oncology, immunology, and inflammation Stage Focus: 5AM Ventures Strategy primarily invests in private therapeutic companies with emphasis on early-stage, particularly Series A companies . The firm also invests pre-Series A through its 4:59 Initiative, which discovers, incubates, and funds breakthrough science through a hands-on internal effort. The 4:59 Initiative often serves as an extension of the operating team to establish proof-of-concept data that will enable Series A financing. Parallel Strategy: 5AM Opportunities Strategy invests in small and mid-cap public and later-stage private biotech and life science companies, representing a distinct strategy focused on public equities and later-stage investments. Check Size & Investment Tickets Based on historical portfolio analysis: Range: $500K-$20M+ depending on stage and fund strategy Series A Focus: $2M-$15M typical range 4:59 Initiative (Pre-Series A): $250K-$2M range Fund VII: $450M under management (actively deploying 2025-2026) Opportunities II: $300M under management (public/late-stage focus) 5AM demonstrates flexibility in check size, ranging from small pre-seed/seed investments through significant Series A participations and follow-ons for promising companies. Lead Tendency & Decision Process Lead Tendency: Both (leads and participates) The firm demonstrates a balanced approach to leading and participating in rounds. Recent examples include participations in Kinaset Therapeutics ($103M Series B, January 2026), Precede Biosciences ($83.5M, January 2026), and Mendra ($82M Series A, January 2026). Decision Process: Partnership model With multiple Managing Partners and Partners, the firm uses a partnership-driven approach. Multiple team members source and vet deals, with Partners specializing in different therapeutic areas and investment types. Decision Timeline: 2-4 weeks (estimated based on fund size and typical biotech due diligence requirements) Recent Activity & Fund Status Fund Status: Actively deploying 5AM Ventures demonstrates strong recent deployment velocity with recent investments in January 2026 (Mendra $82M Series A, Precede $83.5M, Kinaset $103M Series B) and December 2025 (CAMP4 $30M post-IPO offering, GSK strategic collaboration). The firm has made 250+ investments historically and maintains a portfolio of 80+ active companies. Portfolio Highlights & Notable Companies Recent/Notable Portfolio Companies: CAMP4 Therapeutics (IPO October 2024) - RNA-modulating therapeutics Artiva Biotherapeutics (IPO July 2024) - NK cell immunotherapies Ensoma - In vivo gene therapy for rare genetic disorders Kinaset Therapeutics - Inhaled respiratory disease therapeutics Precede Biosciences - Next-generation liquid biopsy/precision diagnostics Mendra - Rare disease therapeutics using AI NodThera - Chronic inflammation disease treatments Nouscom - Cancer immunotherapy (neoantigen vaccines) Karius - Liquid biopsy using NGS Lifordi - Immune-targeted antibody-drug conjugates TMRW - Cryopreservation for IVF Rallybi - Rare disease therapeutics Entrada - Intracellular biologic delivery Homology Medicines - Gene editing/therapy 50+ additional exits via IPO, acquisition, or merger Team Leadership Managing Partners: Kush M Parmar, MD, PhD Andy J. Schwab Key Partners: Michael Calore - Head of Investor Relations John Kelly - CFO & COO Deborah Palestrant, PhD - Executive Chair, 4:59 Initiative Anna Yaeger - Head of Public Equities Max Farina, MD - Principal Katie Bodner Spielberg, PhD - Principal The firm maintains an extensive network of Venture Advisors and Partners with deep life science expertise. Strategic Pillars & Differentiation 1. Hands-On Operating Approach Going beyond traditional board roles, 5AM team members assume short-term operating roles and provide continuous guidance on strategy and management team development. 2. Experienced Team Over 100 years of combined operational experience as CEOs and senior leaders positions the firm as true entrepreneur partners. 3. Capital Efficiency & Shortened Realization Time Focus on investments expected to generate returns within 3-5 years through validated development-stage assets and technologies with clearer commercialization paths. 4. Low Loss Rate Focus Unlike VCs focused only on best performers, 5AM seeks to maximize shareholder returns across ALL portfolio companies through active management. 5. Diversity, Equity & Inclusion Committed to DEI as a core principle in catalyzing breakthrough science and enabling development of transformative therapies. 4:59 Initiative The 4:59 Initiative is 5AM's internal effort to discover, incubate, and fund breakthrough science. The team partners alongside academics and entrepreneurs to establish proof-of-concept data for Series A financing. Geographic Focus Primary Offices: San Francisco, CA (4 Embarcadero Center, Suite 3110) - headquarters Boston, MA (200 Clarendon Street, 22nd Floor) Investment Scope: US-focused with selective international investments in life sciences companies with breakthrough potential Founder & Company Preferences 5AM seeks to back: Best scientists in leading-edge fields Well-established entrepreneurs with track records Companies solving important healthcare needs Management teams with deep life science/clinical expertise Innovative technologies with clear commercialization paths Engagement Model Board role or observer seat Active operational support Strategic guidance on company strategy and management Business development and fundraising support Connection to networks of life science leaders Competitive Positioning 5AM Ventures differentiates through: Long track record (founded 2002, 250+ investments) Hands-on operating approach beyond passive board roles Experienced team with 100+ years CEO and leadership experience Low loss rate philosophy Unique incubation model via 4:59 Initiative Multiple fund strategies (private equity and public equities) Strong exit history (50+ successful exits) Deep life science expertise in biopharm, drug delivery, instruments Fund Economics Current Funds: 5AM Ventures VII: $450M (active deployment) 5AM Opportunities II: $300M (public/later-stage) Total AUM: $750M+